Comparative Pharmacology
Head-to-head clinical analysis: TRIFLURIDINE versus VITRASERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIFLURIDINE versus VITRASERT.
TRIFLURIDINE vs VITRASERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trifluridine is a thymidine analog that inhibits thymidylate synthase and incorporates into DNA, leading to DNA damage and cell death.
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
Topical: Apply one drop to affected eye every 2 hours while awake (maximum 9 drops/day) until re-epithelialization, then one drop every 4 hours for 7 days. Ophthalmic solution 1%.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
None Documented
None Documented
Clinical Note
moderateTrifluridine + Digoxin
"Trifluridine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTrifluridine + Digitoxin
"Trifluridine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTrifluridine + Deslanoside
"Trifluridine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTrifluridine + Acetyldigitoxin
"Trifluridine may decrease the cardiotoxic activities of Acetyldigitoxin."
The terminal elimination half-life of trifluridine is approximately 12-18 hours. This prolonged half-life supports twice-daily dosing and provides sustained exposure for antiviral activity.
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Renal excretion accounts for approximately 40-50% of the administered dose, primarily as the inactive metabolite 5-trifluorothymidine. Fecal excretion is minimal (<5%). The remainder is eliminated via metabolic degradation.
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Category C
Category C
Antiviral
Antiviral